Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and Nanobiotix (NBTX)
TipRanks (Fri, 25-Sep 8:30 AM ET)
H.C. Wainwright Sticks to Its Buy Rating for Nanobiotix (0QAV)
TipRanks (Fri, 25-Sep 6:36 AM ET)
Nanobiotix GAAP EPS of -€0.70, revenue of €5.6M
Seeking Alpha News (Thu, 24-Sep 4:31 PM ET)
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
Globe Newswire (Thu, 24-Sep 4:15 PM ET)
Nanobiotix Updates Share Capital and Voting Rights as of August 31, 2026
TipRanks (Tue, 22-Sep 4:46 PM ET)
Voting Rights and Shares Capital of the Company
Globe Newswire (Tue, 22-Sep 4:15 PM ET)
Globe Newswire (Mon, 14-Sep 2:00 AM ET)
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 9-Sep 4:15 PM ET)
Nanobiotix Secures $71 Million Royalty Agreement—Extends Cash Runway and Advances Cancer Pipeline
Market Chameleon (Fri, 31-Oct 3:08 AM ET)
Market Chameleon (Fri, 24-Oct 3:34 AM ET)
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Nanobiotix S.A. - Adss trades on the NASDAQ stock market under the symbol NBTX.
As of September 25, 2026, NBTX stock price declined to $33.31 with 121,762 million shares trading.
NBTX has a beta of 0.44, meaning it tends to be less sensitive to market movements. NBTX has a correlation of 0.00 to the broad based SPY ETF.
NBTX has a market cap of $1.70 billion. This is considered a Small Cap stock.
In the last 3 years, NBTX traded as high as $57.14 and as low as $2.76.
The top ETF exchange traded funds that NBTX belongs to (by Net Assets): APIE.
NBTX has outperformed the market in the last year with a return of +125.8%, while the SPY ETF gained +18.4%. However, in the most recent history, NBTX shares have underperformed the stock market with its stock returning -3.3% in the last 3 month period and -10.0% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.
NBTX support price is $31.93 and resistance is $34.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBTX shares will trade within this expected range on the day.